NASDAQ, CAPS - Capstone Therapeutics Corp
Prior to November 26, 2003, we developed, manufactured and marketed proprietary,
technologically advanced orthopedic products designed to promote the healing of
musculoskeletal bone and tissue, with particular emphasis on fracture healing
and spine repair. Our product lines included bone growth stimulation and
fracture fixation devices including the OL1000 product line, SpinaLogic? and
OrthoFrame/Mayo, which we sometimes refer to as our ?Bone Device Business.?
On November 26, 2003, we sold our Bone Device Business. Our principal business
remains focused on tissue repair, although through biopharmaceutical approaches
rather than through the use of medical devices.
On August 5, 2004, we purchased substantially all of the assets and intellectual
property of Chrysalis Biotechnology, Inc. (?CBI?), including its exclusive
worldwide license for Chrysalin for all medical indications. We became a
development stage entity commensurate with the acquisition. ...
Read SEC Filing on NASDAQ.com »